Clinical Trials Logo

Filter by:
NCT ID: NCT05926076 Not yet recruiting - COVID-19 Clinical Trials

COVID-19 Infection

Start date: July 25, 2023
Phase:
Study type: Observational

Post-transplant patients with COVID-19 infection who attended Shenzhen No. 3 Hospital from December 2022 to February 2023, and enrolled the general population with COVID-19 infection who were hospitalized during the same period, matched by age and gender.

NCT ID: NCT05925803 Recruiting - Systemic Sclerosis Clinical Trials

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

DAISY
Start date: November 8, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

NCT ID: NCT05925764 Recruiting - Lung Adenocarcinoma Clinical Trials

Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma

Start date: May 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the performance of a whole slide image based deep learning signature for predicting the novel grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.

NCT ID: NCT05925751 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Start date: May 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

NCT ID: NCT05925738 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer

Start date: May 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting aggressive histological pattern in resected non-small cell lung cancer based on a multicenter prospective cohort.

NCT ID: NCT05925504 Recruiting - Clinical trials for Lower Risk MDS Per IPSS-R

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).

NCT ID: NCT05925452 Not yet recruiting - Clinical trials for Active Systemic Juvenile Idiopathic Arthritis

To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

Start date: July 16, 2023
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, open-label Phase IIb clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.

NCT ID: NCT05925413 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma

Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. The goal of this clinical trial is to evaluated the efficacy and safety of cadonilimab combined with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma.

NCT ID: NCT05925335 Recruiting - Heart Failure Clinical Trials

The China Mviv Registry

Start date: July 11, 2023
Phase: N/A
Study type: Interventional

Mitral valve disease is the most common structure heart disease, and surgical valve replacement is an important treatment for severe mitral valve disease. There are 2 types of valve often been used, mechanical or biological protheses valves. Mechanical valve requires lifelong use of anticoagulants and take the risk of bleeding through all lifetime, but bioprotheses valve do not..

NCT ID: NCT05925309 Recruiting - Biliary Atresia Clinical Trials

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.